MethodsRetrospective case series
Participants and Country57 patients with initial diagnosis of CUP
Interventions40 patients had 6 or 10 cycles of vincristine, doxorubicin and cyclophosphamide (VAC)
17 patients VAC alternating with cisplatin and etoposide (PE) for six cycles.
OutcomesResponse rate, overall survival.
NotesAfter histologic review, six tumours were reclassified as non-Hodgkin’s lymphoma (NHL), one as hepatocarcinoma, and one as adenocarcinoma. Lymphoma cases accounted for 6/11 treatment responders.

From: Guideline chapter 5, Systemic Therapy

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.